In accordance with Section 287(a) of Title 35 of the United States Code, the following list identifies Sanofi’s rights in U.S. patents associated with the listed products. This list may be a subset of Sanofi’s rights in U.S. patents directed to the relevant product. The absence of a product or a U.S. Patent number from this list does not constitute a waiver of Sanofi’s patent, trademark, or other intellectual property rights.

  • Alprolix®
    [Coagulation Factor IX (Recombinant), Fc Fusion Protein]
    U.S. Patent No. 7,404,956
    U.S. Patent No. 10,588,949
    U.S. Patent No. 10,058,480
    U.S. Patent No. 10,849,823

    ALTUVIIIO™
    [Antihemophilic Factor (Recombinant),
    Fc-VWF-XTEN Fusion Protein-ehtl]
    U.S. Patent No. 8,673,860
    U.S. Patent No. 9,371,369
    U.S. Patent No. 10,138,291
    U.S. Patent No. 10,421,798
    U.S. Patent No. 11,192,936
    U.S. Patent No. 11,370,827

    Cablivi®
    (caplacizumab-yhdp)
    U.S. Patent No. 7,807,162
    U.S. Patent No. 8,372,398
    U.S. Patent No. 10,035,862

    Caprelsa®
    (vandetanib) Tablets
    U.S. Patent No. 8,067,427

    Cerdelga®
    (eliglustat) capsules
    U.S. Patent No. 7,196,205
    U.S. Patent No. 11,458,119

    Dupixent®
    (dupilumab) Injection
    is a product in collaboration with Regeneron.
    U.S. Patent No. 7,608,693
    U.S. Patent No. 8,945,559
    U.S. Patent No. 10,435,473
    U.S. Patent No. 9,238,692
    U.S. Patent No. 11,059,896
    U.S. Patent No. 8,735,095

    Eloctate®
    [Antihemophilic Factor (Recombinant), Fc Fusion Protein]
    U.S. Patent No. 7,404,956
    U.S. Patent No. 8,329,182
    U.S. Patent No. 9,623,088
    U.S. Patent No. 10,058,480
    U.S. Patent No. 10,849,823

    Enjaymo™
    (sutimlimab-jome) injection, for intravenous use
    U.S. Patent No. 8,877,197
    U.S. Patent No. 8,945,562
    U.S. Patent No. 10,450,382

    Jevtana®
    (cabazitaxel) Injection
    U.S. Patent No. 7,241,907

    Kevzara®
    (sarilumab) Injection is a product in collaboration with Regeneron.
    U.S. Patent No. 7,582,298
    U.S. Patent No. 10,072,086
    U.S. Patent No. 11,098,127
    U.S. Patent No. 8,183,014

    Nexviazyme™
    (avalglucosidase alfa-ngpt)
    U.S. Patent No. 8,759,501

    Rezurock®
    (belumosudil) tablets
    U.S. Patent No. 8,357,693

    Sarclisa®
    (isatuximab-irfc)
    U.S. Patent No. 8,153,765

    Soliqua® 100/33
     (insulin glargine and lixisenatide) injection
    100 Units/mL and 33 mcg/mL
    U.S. Patent No. RE45,313
    U.S. Patent No. 9,526,764
    U.S. Patent No. 10,117,909
    U.S. Patent No. 10,029,011
    U.S. Patent No. 9,707,176
    U.S. Patent No. 9,717,852

    Toujeo®
    (insulin glargine injection)
    300 Units/mL
    U.S. Patent No. 9,345,750
    U.S. Patent No. 11,213,628
    U.S. Patent No. 10,369,291

    Zaltrap®
    (ziv-aflibercept) Injection for Intravenous Infusion
    U.S. Patent No. 8,110,546
    U.S. Patent No. 8,710,004

  • MenQuadfi™
    (Meningococcal [Groups A, C, Y, W] Conjugate Vaccine)
    U.S. Patent No. 11,147,866

Please See Full Prescribing Information, including Boxed Warning, for Caprelsa, Jevtana, Kevzara,  Nexviazyme, Zaltrap.

MAT-US-2208923-v3.0-05/2023